Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C12H15NO3S |
Molecular Weight | 253.317 |
Optical Activity | ( + ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1
InChI
InChIKey=LJJKNPQAGWVLDQ-SNVBAGLBSA-N
InChI=1S/C12H15NO3S/c14-11(15)7-13-12(16)10(8-17)6-9-4-2-1-3-5-9/h1-5,10,17H,6-8H2,(H,13,16)(H,14,15)/t10-/m1/s1
Thiorphan is the first potent synthetic inhibitor of enkephalinase. Thiorphan displays antinociceptive activity after systemic administration. Thiorphan also inhibits to a lesser extent the widely distributed angiotensin-converting enzyme, a carboxydipeptidase implicated in blood pressure regulation. Thiorphan failed to potentiate allergen-induced airway responses in asthma. Thiorphan significantly reduced the castor oil-induced diarrhea in rats when administered intravenously but not when administered intracerebroventricularly. Racecadotril, via its active metabolite thiorphan, was consistently effective in animal models and patients with various forms of acute diarrhea by inhibiting pathologic (but not basal) secretion from the gut without changing gastro-intestinal transit time or motility.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3479550https://www.ncbi.nlm.nih.gov/pubmed/22661949
Curator's Comment: Ecadotril ((S)-acetorphan) is CNS active in animals when administered parenterally. No human data available.
Originator
Sources: http://adisinsight.springer.com/drugs/800001163https://www.ncbi.nlm.nih.gov/pubmed/7001254
Curator's Comment: Roques, B. P., Schwartz, J. C. & Lecomte, J. M., inventors. Derives d'acides amines et leur application therapeutique. Fr. Pat. 8008601, Apr. 17, 1980; Eur. Pat. Appl. EP 38,758; Apr. 14, 1981.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2994 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3479550 |
|||
Target ID: CHEMBL2642 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3479550 |
|||
Target ID: CHEMBL2642 |
3.5 nM [Ki] | ||
Target ID: CHEMBL2994 |
140.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22661949 |
Primary | Unknown Approved UseUnknown |
||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8872633 |
Palliative | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Dizziness, Headache... Other AEs: Dizziness (grade 1-2, 35%) Sources: Headache (16%) Insomnia (6%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Headache | 16% | 400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Insomnia | 6% | 400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Dizziness | grade 1-2, 35% | 400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive [Activation 11.2202 uM] | ||||
no | ||||
no | ||||
yes [IC50 0.1259 uM] | ||||
yes [IC50 0.3162 uM] | ||||
yes [IC50 0.6918 uM] | ||||
yes [IC50 1.2302 uM] | ||||
yes [IC50 2.512 uM] |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. | 1980 Nov 20 |
|
Thiorphan potentiation of stress-induced analgesia in the mouse. | 1982 Sep 20-27 |
|
Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter. | 1992 Apr |
|
Role of neutral endopeptidase in exercise-induced bronchoconstriction in asthmatic subjects. | 1996 Aug |
|
The effect of inhaled thiorphan on allergen-induced airway responses in asthmatic subjects. | 1996 May |
|
Strategies for access to enantiomerically pure ecadotril, dexecadotril and fasidotril: a review. | 2002 Jun |
|
Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension? | 2005 Nov |
|
Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis. | 2006 Feb |
|
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. | 2008 Oct 15 |
|
Role of mu- and delta-opioid receptors in the nucleus accumbens in cocaine-seeking behavior. | 2009 Jul |
|
A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. | 2012 |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
XJ8Z52GK3X
Created by
admin on Wed Apr 02 18:03:52 GMT 2025 , Edited by admin on Wed Apr 02 18:03:52 GMT 2025
|
PRIMARY | |||
|
95909-00-5
Created by
admin on Wed Apr 02 18:03:52 GMT 2025 , Edited by admin on Wed Apr 02 18:03:52 GMT 2025
|
PRIMARY | |||
|
4369380
Created by
admin on Wed Apr 02 18:03:52 GMT 2025 , Edited by admin on Wed Apr 02 18:03:52 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)